Ariad Pharmaceuticals Inc fka ARIA

[Whosetosay]

For those folks still so new to Ariad '788 science, it is important to add that the huge pod numbers Ariad has presented recently across all Ariad drugs, it is '788 that is expected to triple or quadruple Ariad's business. If successful, '788 will dwarf the combined pod of '113 and Pona.

Still, I think Ariad's more recently announced immuno- research is the most novel, and exciting approach to treating cancer out there, beyond car-T and the other immuno approaches.

Denner can still cash in on these newer developing programs even though they are 4-7 years away. There are at least 3 ways: An all stock deal, A genentech type deal, or a future value chit.